Stifel Nicolaus is out with its report today on ISTA Pharmaceuticals ISTA, downgrading ISTA to Hold.
In its report, Stifel Nicolaus writes, "We move to the sidelines and downgrade ISTA to Hold, under the view that shares are fairly valued. We await signs of renewed momentum in the bromfenac franchise and pipeline."
Shares of ISTA closed Thursday at $7.20.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in